Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2015, Article ID 314041, 10 pages
http://dx.doi.org/10.1155/2015/314041
Review Article

Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality

1Division of Cardiology and Center for Cardiovascular Diseases and Science, LSU Health Science Center, Shreveport, LA 71103, USA
2Division of Cardiovascular Medicine, University of Iowa, Iowa City, IA 52242, USA

Received 18 September 2015; Accepted 24 November 2015

Academic Editor: Hugo A. Katus

Copyright © 2015 Surbhi Chamaria et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” The New England Journal of Medicine, vol. 336, no. 8, pp. 525–533, 1997. View at Google Scholar
  2. W. B. Hood Jr., A. L. Dans, G. H. Guyatt, R. Jaeschke, and J. J. McMurray, “Digitalis for treatment of congestive heart failure in patients in sinus rhythm,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD002901, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A.-J. Ouyang, Y.-N. Lv, H.-L. Zhong et al., “Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation,” The American Journal of Cardiology, vol. 115, no. 7, pp. 901–906, 2015. View at Publisher · View at Google Scholar
  4. M. Vamos, J. W. Erath, and S. H. Hohnloser, “Digoxin-associated mortality: a systematic review and meta-analysis of the literature,” European Heart Journal, vol. 36, no. 28, pp. 1831–1838, 2015. View at Publisher · View at Google Scholar
  5. D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” The Journal of the American Medical Association, vol. 283, no. 15, pp. 2008–2012, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. R. P. Harris, M. Helfand, S. H. Woolf et al., “Current methods of the US Preventive Services Task Force: a review of the process,” American Journal of Preventive Medicine, vol. 20, no. 3, pp. 21–35, 2001. View at Google Scholar · View at Scopus
  7. M. Levine, S. Walter, H. Lee, T. Haines, A. Holbrook, and V. Moyer, “Users' guides to the medical literature. IV. How to use an article about harm. Evidence-Based Medicine Working Group,” The Journal of the American Medical Association, vol. 271, no. 20, pp. 1615–1619, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Hallberg, J. Lindbäck, B. Lindahl, U. Stenestrand, and H. Melhus, “Digoxin and mortality in atrial fibrillation: a prospective cohort study,” European Journal of Clinical Pharmacology, vol. 63, no. 10, pp. 959–971, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. G. Thompson and J. P. T. Higgins, “How should meta-regression analyses be undertaken and interpreted?” Statistics in Medicine, vol. 21, no. 11, pp. 1559–1573, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. G. Thompson and S. J. Sharp, “Explaining heterogeneity in meta-analysis: a comparison of methods,” Statistics in Medicine, vol. 18, no. 20, pp. 2693–2708, 1999. View at Google Scholar
  12. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. V. Freeman, K. Reynolds, M. Fang et al., “Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study,” Circulation: Arrhythmia and Electrophysiology, vol. 8, no. 1, pp. 49–58, 2015. View at Publisher · View at Google Scholar
  14. L. Fauchier, C. Grimard, B. Pierre et al., “Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure,” The American Journal of Cardiology, vol. 103, no. 2, pp. 248–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. T.-F. Chao, C.-J. Liu, S.-J. Chen et al., “Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study,” Canadian Journal of Cardiology, vol. 30, no. 10, pp. 1190–1195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Shah, M. Avgil Tsadok, C. A. Jackevicius, V. Essebag, H. Behlouli, and L. Pilote, “Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure,” The American Journal of Cardiology, vol. 114, no. 3, pp. 401–406, 2014. View at Publisher · View at Google Scholar
  17. L. A. Allen, G. C. Fonarow, D. N. Simon et al., “Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort,” Journal of the American College of Cardiology, vol. 65, pp. 2691–2698, 2015. View at Google Scholar
  18. M. G. Whitbeck, R. J. Charnigo, P. Khairy et al., “Increased mortality among patients taking digoxin—analysis from the AFFIRM study,” European Heart Journal, vol. 34, no. 20, pp. 1481–1488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Gjesdal, J. Feyzi, and S. B. Olsson, “Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data,” Heart, vol. 94, no. 2, pp. 191–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. P. Turakhia, P. Santangeli, W. C. Winkelmayer et al., “Increased mortality associated with digoxin in contemporary patients with atrial fibrillation findings from the TREAT-AF study,” Journal of the American College of Cardiology, vol. 64, pp. 660–668, 2014. View at Google Scholar
  21. D. Pastori, A. Farcomeni, T. Bucci et al., “Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation,” International Journal of Cardiology, vol. 180, pp. 1–5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Friberg, N. Hammar, and M. Rosenqvist, “Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF),” Heart, vol. 96, no. 4, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Rodríguez-Mañero, F. Otero-Raviña, J. García-Seara et al., “Outcomes of a contemporary sample of patients with atrial fibrillation taking Digoxin: results from the AFBAR study,” Revista Espanola de Cardiologia, vol. 67, no. 11, pp. 890–897, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. B. A. Mulder, D. J. Van Veldhuisen, H. J. G. M. Crijns et al., “Digoxin in patients with permanent atrial fibrillation: data from the RACE II study,” Heart Rhythm, vol. 11, no. 9, pp. 1543–1550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Gheorghiade, G. C. Fonarow, D. J. van Veldhuisen et al., “Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial,” European Heart Journal, vol. 34, no. 20, pp. 1489–1497, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. V. V. Georgiopoulou, A. P. Kalogeropoulos, G. Giamouzis et al., “Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy,” Circulation—Heart Failure, vol. 2, no. 2, pp. 90–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 64, no. 21, pp. e1–e76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. S. Rathore, J. P. Curtis, Y. F. Wang, M. R. Bristow, and H. M. Krumholz, “Association of serum digoxin concentration and outcomes in patients with heart failure,” The Journal of the American Medical Association, vol. 289, no. 7, pp. 871–878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Mazur and M. E. Anderson, “Digoxin and cardiac arrhythmias: an update,” Cardiac Electrophysiology Review, vol. 2, no. 2, pp. 222–224, 1998. View at Publisher · View at Google Scholar
  30. J. A. Kastor and P. M. Yurchak, “Recognition of digitalis intoxication in the presence of atrial fibrillation,” Annals of Internal Medicine, vol. 67, no. 5, pp. 1045–1054, 1967. View at Publisher · View at Google Scholar · View at Scopus